GHRH(1-29) analogue
Sermorelin
Truncated GHRH analogue that stimulates pituitary GH secretion via GHRH receptors.
Primary Mechanism of Action
Clinical / Scientific
Sermorelin is GHRH 1–29, sufficient for GHRHR activation and physiologic-style GH pulses, historically used in diagnostic and selected paediatric contexts in some markets.
Pathway Targets
GHRH receptor
Scientific explanation
Somatotroph agonism.
Pathway Convergence
Clinical / Scientific
Target → pathway → downstream effect → biological consequence. This is a mechanistic map, not a treatment claim.
Receptor to physiology
Target to downstream effect: GHRH receptor
Mechanistically Relevant Repurposed & Adjunctive Applications
Research peptide context
PreclinicalMechanistic rationale
Catalogued as a research peptide. Mechanistic statements below describe known or pathway biology and do not establish a licensed therapeutic indication.
Mechanistic Application Matrix
| Biological Target | Mechanism | Potential Relevance | Evidence Level |
|---|---|---|---|
| GHRHR | Agonism | GH pulses | Established mechanism |
In Plain Language
Sermorelin is a short official-style copy of the hormone that asks the pituitary for growth hormone.
Compounds Sharing Pathways
Other library compounds whose structured pathway data overlap this ingredient. Shared pathways are not combination recommendations.
GHRH receptor
Mechanistic information is provided for scientific and educational purposes. Discussion of biological pathways or investigational applications does not establish clinical efficacy or constitute individualized medical advice.